Related references
Note: Only part of the references are listed.Asthma exacerbations on benralizumab are largely non-eosinophilic
Sophie M. Poznanski et al.
ALLERGY (2021)
Evaluation of Diffuse Type 2 Dominant or Eosinophilic Chronic Rhinosinusitis With Corticosteroid IrrigationAfter Surgical Neosinus Cavity Formation
William Li et al.
JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY (2021)
Suboptimal treatment response to anti-IL-5 monoclonal antibodies in severe eosinophilic asthmatics with airway autoimmune phenomena
Manali Mukherjee et al.
EUROPEAN RESPIRATORY JOURNAL (2020)
Blood Eosinophil Depletion with Mepolizumab, Benralizumab, and Prednisolone in Eosinophilic Asthma
Angela M. Moran et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2020)
Exacerbations of Severe Asthma While on Anti-IL-5 Biologics
A. Bhalla et al.
JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY (2020)
Effect of monoclonal antibody drug therapy on mucosal biomarkers in airway disease: A systematic review
Sophie Walter et al.
CLINICAL AND EXPERIMENTAL ALLERGY (2020)
Increased Serum IgG4 Associates with Asthma and Tissue Eosinophilia in Chronic Rhinosinusitis Patients
Mahnaz Ramezanpour et al.
PATHOGENS (2020)
EUFOREA consensus on biologics for CRSwNP with or without asthma
Wytske J. Fokkens et al.
ALLERGY (2019)
The spectrum of therapeutic activity of mepolizumab
Carlo Cavaliere et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2019)
Biologics for the treatment of chronic rhinosinusitis with nasal polyps - state of the art
Lei Ren et al.
WORLD ALLERGY ORGANIZATION JOURNAL (2019)
Significance of IgG4-positive cells in severe eosinophilic chronic rhinosinusitis
Takahisa Koyama et al.
ALLERGOLOGY INTERNATIONAL (2019)
Modulation of blood inflammatory markers by benralizumab in patients with eosinophilic airway diseases
Sriram Sridhar et al.
RESPIRATORY RESEARCH (2019)
Biologics in Chronic Rhinosinusitis: An Update and Thoughts for Future Directions
Kristine A. Smith et al.
AMERICAN JOURNAL OF RHINOLOGY & ALLERGY (2018)
Clinical Efficacy of Benralizumab in Patients With Severe, Uncontrolled Eosinophilic Asthma and Nasal Polyposis: Pooled Analysis of the SIROCCO and CALIMA Trials
Jorge Maspero et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2018)
Benralizumab: From the Basic Mechanism of Action to the Potential Use in the Biological Therapy of Severe Eosinophilic Asthma
Corrado Pelaia et al.
BIOMED RESEARCH INTERNATIONAL (2018)
High tissue eosinophilia as a marker to predict recurrence for eosinophilic chronic rhinosinusitis: a systematic review and meta-analysis
Tobial McHugh et al.
INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY (2018)
Targeting the Interleukin-5 Pathway for Treatment of Eosinophilic Conditions Other than Asthma
Florence Roufosse
FRONTIERS IN MEDICINE (2018)
Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience
Rosalia Emma et al.
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE (2018)
Increased number of IgG4-positive plasma cells in chronic rhinosinusitis
Keiko Ohno et al.
ACTA OTO-LARYNGOLOGICA (2017)
Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma
Parameswaran Nair et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab
Corrado Pelaia et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2017)
Mepolizumab Attenuates Airway Eosinophil Numbers, but Not Their Functional Phenotype, in Asthma
Elizabeth A. Kelly et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2017)
Pathogenesis of eosinophilic chronic rhinosinusitis
Said Ahmad Shah et al.
JOURNAL OF INFLAMMATION-LONDON (2016)
Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial
Eugene R. Bleecker et al.
LANCET (2016)
Benralizumab, an anti-interleukin-5 receptor a monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial
J. Mark FitzGerald et al.
LANCET (2016)
Clinical usefulness of mepolizumab in severe eosinophilic asthma
Francesco Menzella et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2016)
Remodeling changes of the upper airway with chronic rhinosinusitis
Henry P. Barham et al.
INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY (2015)
Should lung biopsies be performed in patients with severe asthma?
Daniel Doberer et al.
EUROPEAN RESPIRATORY REVIEW (2015)
Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma
Elisabeth H. Bel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma
Hector G. Ortega et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Histopathological evaluation of chronic rhinosinusitis: A critical review
Nancy Jiang et al.
AMERICAN JOURNAL OF RHINOLOGY & ALLERGY (2013)
Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia
Michel Laviolette et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2013)
Asthmatic Granulomatosis A Novel Disease with Asthmatic and Granulomatous Features
Sally E. Wenzel et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2012)
Benralizumab - a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity - a novel approach for the treatment of asthma
Aasia Ghazi et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2012)
Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial
Ian D. Pavord et al.
LANCET (2012)
Structured histopathology profiling of chronic rhinosinusitis in routine practice
Kornkiat Snidvongs et al.
INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY (2012)
IgG4-related chronic rhinosinusitis: A new clinical entity of nasal disease
Hideaki Moteki et al.
ACTA OTO-LARYNGOLOGICA (2011)
Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma
Pranabashis Haldar et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics
A Menzies-Gow et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2003)
Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway
PT Flood-Page et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2003)
Features of airway remodeling and eosinophilic inflammation in chronic rhinosinusitis: Is the histopathology similar to asthma?
JU Ponikau et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2003)
Share Paper
